Get the Stockscreener App
0.5019
0.43%
0.0057
X 4 Pharmaceuticals Inc stock is traded at $0.5019, with a volume of 989.33K.
It is up +0.43% in the last 24 hours and down -16.60% over the past month.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$0.5076
Open:
$0.5047
24h Volume:
989.33K
Relative Volume:
0.28
Market Cap:
$85.48M
Revenue:
-
Net Income/Loss:
$-101.17M
P/E Ratio:
-0.8507
EPS:
-0.59
Net Cash Flow:
$-96.57M
1W Performance:
+11.85%
1M Performance:
-16.60%
6M Performance:
-32.83%
1Y Performance:
-32.15%
1-Day Range:
$0.47
$0.534
1-Week Range:
$0.425
$0.5375
52-Week Range:
$0.2612
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
0.5019 | 85.48M | 0 | -101.17M | -96.57M | -0.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.11 | 109.85B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.56 | 75.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
652.82 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.40 | 32.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.50 | 26.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
January 2025's Top US Penny Stocks To Consider - Simply Wall St
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
EVP Research Swayze Eric converted options into 19,160 shares and sold $235,678 worth of shares (7,176 units at $32.84), increasing direct ownership by 35% to 45,670 units (SEC Form 4) - Quantisnow
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
X4 Pharmaceuticals (NASDAQ:XFOR) Earns Buy Rating from HC Wainwright - Defense World
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - Scrip
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine - Research Tree
X4 Pharmaceuticals (NASDAQ:XFOR) Receives Buy Rating from HC Wainwright - MarketBeat
Jane Street Group LLC Increases Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals Partners with Norgine for Mavorixafor Expansion - TipRanks
X4 Pharmaceuticals, Inc. and Norgine Pharma UK Limited Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - Marketscreener.com
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - Yahoo Finance
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Brookline Capital Management Estimates XFOR FY2024 Earnings - Defense World
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PR Newswire
Brokers Set Expectations for XFOR FY2024 Earnings - MarketBeat
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Fragile X Syndrome Clinical and Non-Clinical Studies, Key - openPR
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Geode Capital Management LLC Trims Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Jagsonpal Pharmaceuticals record date for 1:2.5 stock split today - The Economic Times
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - Quantisnow
Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4) - Quantisnow
Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4) - Quantisnow
SEC Form 4 filed by Director Macartney Lawson - Quantisnow
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations - Star Local Media
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - Yahoo Finance
Prescription Drug Costs | Pros, Cons, Debate, Arguments, Economy, Laws, Government, & Regulation - Britannica
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals Inc (NASDAQ: XFOR): An Enticing Stock To Watch - Stocks Register
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Chicago Star Media
Exciting Hire at Terns Pharma! New Employee Receives Special Stock Grant! - Jomfruland.net
Telangana: Medicines worth Rs 2 crore seized - Medical Dialogues
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Acquired by State Street Corp - Defense World
Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com - Defense World
Stifel Financial Corp Sells 41,819 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Lithium Americas Corp. (NYSE:LAC) Shares Sold by Stifel Financial Corp - Defense World
Definitive Healthcare Corp. (NASDAQ:DH) Shares Sold by Stifel Financial Corp - Defense World
Stifel Financial Corp Reduces Stock Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) - Defense World
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire
Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4) - Quantisnow
How To Check Senores Pharmaceuticals IPO Allotment Status? Find Latest GMP, Listing Date And More - NDTV Profit
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - Simply Wall St
Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com - Defense World
Senores Pharmaceuticals IPO oversubscribed 93.69 times; check allotment and listing details - Zee Business
Senores Pharmaceuticals IPO Day 3 Highlights: Issue booked 93.41 times on third day; check GMP & other details | Stock Market News - Mint
Senores Pharmaceuticals IPO: Issue subscribed 93 times on last day; here’s how to check allotment status - Upstox
Senores Pharmaceuticals IPO Subscribed 93.41 Times On Day 3: Check GMP, Price Band And More - NDTV Profit
Layoff Tracker: Stubborn Layoff Trend Continues Across Biopharma in 2024 - BioSpace
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):